A research paper on next-generation antibody-drug conjugate (ADC) technology by Cyron Therapeutics' research team has been published in the prestigious medical journal 'Nature Medicine'.
The research introduces 'Dual-Lock ADC' technology that innovatively solves the limitations of existing ADCs - drug detachment and normal tissue damage. This technology uses two different binding mechanisms designed to selectively release drugs only in cancer cells.
Animal experiments showed that Dual-Lock ADC doubled therapeutic efficacy compared to conventional ADCs while reducing toxicity to normal tissues by 80%. Its exceptional effectiveness in refractory solid tumors indicates very high potential for future clinical application.
This research achievement represents international recognition of Cyron Therapeutics' original research capabilities, and the company is accelerating clinical development to help patients as soon as possible.